Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy.

Related Articles

Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy.

Oncoimmunology. 2016;5(11):e1238558

Authors: Chen J, Zhao Y, Chu X, Lu Y, Wang S, Yi Q

Abstract
Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cells in vivo. Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.

PMID: 27999759 [PubMed]

http://ift.tt/2hYrHdu